Expert recommendations for the management of autoimmune bullous diseases during the COVID‐19 pandemic

Kasperkiewicz, Michael; Schmidt, Enno; Fairley, Janet A.; Joly, P.; Payne, Aimee; Yale, M.; Zillikens, Detlef; Woodley, David T.

doi:10.1111/jdv.16525

Cited by 56 publications

(83 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…A group of specialists in autoimmune blistering diseases considered that azathioprine, mycophenolate mofetil/sodium, cyclophosphamide, methotrexate and cyclosporine may be stopped for the duration of COVID-19 symptoms, whereas topical corticosteroids, prednis(ol)one ≤10 mg/day, dapsone/sulphapyridine, doxycycline/tetracycline, colchicine and intravenous immunoglobulins can be continued. 8 The European Task Force on Atopic Dermatitis (ETFAD) noted that immune-modulating drugs used for treating AD also affect the severity of comorbidities such as asthma, chronic obstructive lung disease, eosinophilic oesophagitis, kidney disease and severe allergies and that the abrupt termination of a stable systemic treatment regimen may lead to exacerbations of AD and other comorbidities. 6 Lebwohl et al, based on 'precoronavirus era' studies, noted that discontinuation of some biologics can result in loss of response when treatments are reintroduced or even result in the formation of antibodies to the discontinued biologic.…”

Section: Patients With Skin Diseases Infected By Covid-19mentioning

confidence: 99%

“…6 Experts on autoimmune blistering diseases also endorsed these recommendations. 8 Systemic treatment is usually prescribed to patients who have severe refractory signs and dramatically impaired QoL. If possible, long-term systemic treatment should be continued in a standard regime and may help patients avoid both clinical and psychological consequences of treatment discontinuation and associated decrease of their QoL.…”

Section: Patients With Skin Disease At a Risk Of Covid-19 Infectionmentioning

confidence: 99%

See 1 more Smart Citation

Position statement of the European Academy of Dermatology and Venereology Task Force on Quality of Life and Patient Oriented Outcomes on quality of life issues in dermatologic patients during the COVID‐19 pandemic

Chernyshov

Tómas-Aragonés

Augustin

et al. 2020

Acad Dermatol Venereol

View full text Add to dashboard Cite

The pandemic of COVID-19 is a global challenge for health care, and dermatologists are not standing apart from trying to meet this challenge. The European Academy of Dermatology and Venereology (EADV) has collected recommendations from its Task Forces (TFs) related to COVID-19. The Journal of the EADV has established a COVID-19 Special Forum giving free access to related articles. The psychosocial effects of the pandemic, an increase in contact dermatitis and several other skin diseases because of stress, disinfectants and protective equipment use, especially in healthcare workers, the temporary limited access to dermatologic care, the dilemma whether or not to pause immunosuppressive therapy, and, finally, the occurrence of skin lesions in patients infected by COVID-19 all contribute to significant quality of life (QoL) impairment. Here, we present detailed recommendations of the EADV TF on QoL and patient-oriented outcomes on how to improve QoL in dermatologic patients during the COVID-19 pandemic for several different groups of patients and for the general population.

show abstract

Section: Patients With Skin Diseases Infected By Covid-19mentioning

confidence: 99%

Section: Patients With Skin Disease At a Risk Of Covid-19 Infectionmentioning

confidence: 99%

Position statement of the European Academy of Dermatology and Venereology Task Force on Quality of Life and Patient Oriented Outcomes on quality of life issues in dermatologic patients during the COVID‐19 pandemic

Chernyshov

Tómas-Aragonés

Augustin

et al. 2020

Acad Dermatol Venereol

View full text Add to dashboard Cite

show abstract

“…One of them had an exacerbation of symptoms and treatments were resumed. Expert recommendations about the management of autoimmune bullous disease during the COVID-19 pandemic suggest to weigh the risks about rituximab or apheresis treatments against conventional immunomodulatory regimens [14]. Maintenance TPE treatment in a case of Graves orbitopathy (not responding to antithyroid drugs) was suspended during the outbreak, in accordance with Endocrinologists.…”

Section: Discussionmentioning

confidence: 99%

Impact of COVID-19 pandemic in the activity of a Therapeutic Apheresis unit in Italy

Colpo

Astolfi²,

Tison

et al. 2020

Transfusion and Apheresis Science

View full text Add to dashboard Cite

The recent Coronavirus Disease 2019 (COVID-19) outbreak has led to profound and rapid changes in the Italian and Veneto Region Healthcare System. This context also includes the quick reorganization which the Apheresis Unit (AU) of the Padova University Hospital, i.e. the Regional Reference Center for Therapeutic Apheresis (TA), had to face. Material and Methods: The study retrospectively evaluated the TA activity (procedures performed, patients treated and consultations) during the COVID-19 pandemic, from March to April 2020, comparing the activity in the same time period in 2018 and 2019. Results: In the period analyzed, a significant reduction in both the total number of procedures performed and of patients treated, respectively by 17 % and 16 % for the procedures and by 19 % and 20 % for patients treated compared to the same period of 2018 and 2019, respectively, was observed. A concomitant reduction in requests for TA consultation for new patients (both outpatients and inpatients) was observed, equal to 32 % and 21 % compared to 2018 and 2019, respectively. Conclusion: Many reasons determined the observed reduction in the TA activity during the recent COVID-19 outbreak. The AU itself was quickly reorganized in terms of location and supplies to allow for the appropriate COVID-19 patients care. Many non urgent cases, after multidisciplinary discussion between Clinicians and Apheresis Specialists, were deferred, maintaining close phone and e-mail contact with patients.

show abstract

“…First, the longterm immunomodulating approaches employed on the treatment of these diseases may inhibit antiviral immunity and predispose to worse course of COVID-19. 43 Additionally, a potential exacerbation of the autoimmunerelated oral lesions may occur if the patients are advised to discontinue such therapy during the pandemic. 44 Several guidelines have been proposed to SARS-CoV-2 infection control to provide safe dental practice.…”

Section: Covid-19 and Immunocompromised Patientsmentioning

confidence: 99%

Immunocompromised patients and coronavirus disease 2019: a review and recommendations for dental health care

2020

View full text Add to dashboard Cite

In less than four months, an unprecedented pandemic changed the world scenario, closing institutions and commerce, paralyzing sports championships, blocking frontiers, and putting almost all populations in a house quarantine regimen. Immunocompromised patients are within the high-risk group to severe outcomes from COVID-19. However, there is no clear evidence of the association between impaired immune host status and complications from SARS-CoV-2 infection so far. The virus is transmitted by inhalation or direct contact with infected secretions, and therefore the dental office is a highly susceptible environment for such transmission. Here, we review the literature and discuss immunological COVID-19 related issues. We also make suggestions for immunocompromised patients' support in this new emerging context of clinical dental practice. Until comprehensive findings are published, individuals with impaired immunity should be considered as high-risk. Cross infection control procedures for the clinical care of immunocompromised patients should follow the same guidelines that are being proposed for immunocompetent ones. However, during the active outbreak, people under immunosuppressive conditions should not receive elective procedures, even if they do not have symptoms or exposure history to COVID-19, and in case of emergence, care must be done in a separate airborne room. In the pos-pandemic phase, the dental care general recommendations should be the same for all subjects. Changes in the current guidelines have been proposed to SARS-CoV-2 infection control in order to provide the best and safe dental practice. However, they still need to be validated by future studies.

show abstract

Expert recommendations for the management of autoimmune bullous diseases during the COVID‐19 pandemic

Cited by 56 publications

References 5 publications

Position statement of the European Academy of Dermatology and Venereology Task Force on Quality of Life and Patient Oriented Outcomes on quality of life issues in dermatologic patients during the COVID‐19 pandemic

Position statement of the European Academy of Dermatology and Venereology Task Force on Quality of Life and Patient Oriented Outcomes on quality of life issues in dermatologic patients during the COVID‐19 pandemic

Impact of COVID-19 pandemic in the activity of a Therapeutic Apheresis unit in Italy

Immunocompromised patients and coronavirus disease 2019: a review and recommendations for dental health care

Contact Info

Product

Resources

About